A Study of Disease Progression and Anti-HIV Treatments

National Institute of Allergy and Infectious Diseases (NIAID)210 enrolled

Overview

To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Enrollment

210

Conditions

HIV Infections

Interventions

LamivudineDRUG

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients must have: * Prior participation on protocol ACTG 175. PER AMENDMENT 8/27/96: * Patients must be on study/on treatment at the time the protocol study treatment is extended.

Locations (41)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Alabama Therapeutics CRS

Birmingham, Alabama, United States

USC CRS

Los Angeles, California, United States

UCLA CARE Center CRS

Los Angeles, California, United States

Stanford CRS

Palo Alto, California, United States

Ucsd, Avrc Crs

San Diego, California, United States

Ucsf Aids Crs

San Francisco, California, United States

Santa Clara Valley Med. Ctr.

San Jose, California, United States

San Mateo County AIDS Program

Stanford, California, United States

Harbor-UCLA Med. Ctr. CRS

Torrance, California, United States

University of Colorado Hospital CRS

Aurora, Colorado, United States

...and 31 more locations